Vaccines are biological preparations, generally produced from living organisms that enhance immunity against a particular disease. Vaccines that prevent occurrence of a disease are called prophylactic vaccines and in some cases, treat diseases are called therapeutic vaccines. A vaccine is usually made from a weakened or killed form of the disease causing microorganism. The four primary types of vaccines are live attenuated vaccines, inactivated vaccines, conjugate vaccines, and toxoid vaccines. Viral vaccines contain killed or attenuated virus or their product that can activate the immune system to produce antibodies against them. The five types of viral vaccines are live whole viral vaccine, killed whole viral vaccine, subunit vaccine (purified or recombinant viral antigen), anti-idiotype antibodies, and DNA vaccine. Live viral vaccines are prepared by reducing virulence of pathogen, but keeping it alive. Killed viral vaccine consist of virus particle grown on culture and then killed by using heat or formaldehyde. Subunit vaccines (purified or recombinant viral antigen) are created by exposing viral particle in bacteria, yeast, or mammalian cell (an alternative application of recombinant DNA technology for production of hybrid virus vaccines). Anti-idiotype antibodies have the ability to mimic foreign antigen approach that leads to their development as vaccine to induce immunity against virus, bacteria, and protozoa in experimental animals. DNA vaccination involves direct introduction of genetically engineered DNA so that cells directly produce an antigen.

Rise in prevalence of several infectious and non-infectious disease, and technological advancements are projected to drive the global viral vaccines market during the forecast period. Additionally, large number of vaccination programs, government and non-government initiatives, and increase in demand for combined vaccine boost the growth of the market. However, cost associated with storage and transportation of vaccines and limited reimbursement coverage are projected to restrain the global viral vaccines market during the forecast period. Moreover, stringent government regulation for the approval of biological products is likely to hamper the growth of the market in the next few years.

The global viral vaccines market can be segmented based on type of vaccine, indication type, route of administration, distribution channels, and region. In terms of type of vaccine, the global market can be bifurcated into preventive and therapeutic. Based on indication, the global viral vaccines market can be classified into influenza, hepatitis, chickenpox, smallpox, human papillomavirus infection, measles, mumps, rabies, rubella, polio or poliomyelitis, swine flu, yellow fever, and others. In terms of route of administration, the global market can be divided into oral and injectable. Based on distribution channel, the global viral vaccines market can be classified into online pharmacies, hospital pharmacies, and research institutes.

In terms of region, the global viral vaccines market can be segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is expected to account for the largest share of the global market from 2018 to 2026, due to increase in initiatives by the United States Department of Health and Human Services (HHS). This is one of the key factors that encourages immunization programs in the U.S. Europe is expected to be the second largest market for viral vaccines during the forecast period, due to rise in prevalence of infectious diseases, government initiatives, and focused product development. The viral vaccines market in Asia Pacific is expected to expand rapidly during the forecast period. Growth of the market in the region is attributed to increase in awareness about prevention of bacterial diseases, rapidly developing health care infrastructure, and surge in adoption of technology in the region.

Key players operating in the global viral vaccines market are Seqirus A CSL, GlaxoSmithKline plc, Merck & Co., Inc. MedImmune, LLC, Emergent Product Development Gaithersburg, Inc., Novartis, Inc., Protein Sciences Corporation, Sanofi-Aventis U.S. LLC, Sanofi Pasteur, Serum Institute of India Ltd. In 2015, the EU commission approved the merger of Nimenrix and Mencevax vaccines businesses belonging to GlaxoSmithKline.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Viral Vaccines Market

Pre Book